Hints and tips:
...Nonetheless, James Shin, a biopharma analyst at Deutsche Bank, said the sharp increase in biosimilar prescriptions in recent weeks would be “alarming” to AbbVie....
...But most early stage research is done in university laboratories or at small biopharma companies. Do big companies that acquire the likely winners merit more than 20 years of patent protection?...
...The proposed transaction comes amid an apparent uptick in M&A activity across the biopharma sector, which is being driven by a combination of larger pharmaceutical companies seeking new drugs to bolster...
...The biopharma industry said the rewards were justified given the extraordinary efforts made by leaders during the pandemic in developing Covid jabs....
...The market value of listed biopharma groups from China on the Hong Kong, Shanghai and Nasdaq exchanges has surged from $3bn in 2016 to $240bn today, McKinsey said — despite a sharp correction in global biotech...
...“Without question this is the biggest binary event in biopharma in 2021,” said Colin Bristow, an analyst at UBS, referring to the drug’s approval or rejection. How does the drug work?...
...A person close to the company rejected that, pointing to key roles played by Mene Pangalos, head of biopharma R&D, Ruud Dobber, head of the biopharma business, and Pam Cheng, head of global operations and...
...It needs more doses now — but we also need to be ready for the variants,” said Angela Hwang, president of global biopharma for Pfizer, whose vaccine developed with Germany’s BioNTech was the first to win...
...J&J’s deal follows a similar move by the French pharmaceutical group Sanofi, which on Monday said it had agreed to buy San Francisco-based Principia Biopharma in a $3.4bn deal....
...Other deals included Bristol-Myers-Squibb’s $74bn takeover of biotech group Celgene and Pfizer’s $11.4bn acquisition of Array BioPharma....
...Early last year Bristol-Myers Squibb purchased Celgene for $93bn, while Pfizer snapped up Array BioPharma for $11bn in June....
...Biopharma companies, which use cutting edge biology to produce innovative medicines, is risky for investors given the high failure rate that is the hallmark of drug discovery....
...Pfizer has agreed to pay $11.4bn for Array BioPharma, the latest move in an arms race between large pharmaceutical groups to assemble potentially blockbuster cancer treatments....
...company lowered its guidance, on a gaap basis, to between $3.78 and $3.88, compared to its previous forecasts of $4.02 and $4.14, because of costs related to the acquisition of Peloton Therapeutics, a biopharma...
...Revenue from the biopharma division rose 2 per cent year on year but sales at Upjohn dropped 11 per cent while revenue from the consumer healthcare business was down 3 per cent....
...wealth fund is looking to ramp up its investment plans in North America and Asia, the biggest European private equity groups are rushing to raise new mega funds and Pfizer agrees to pay $11.4bn for Array BioPharma...
...It was followed by Pfizer’s $11.4bn purchase of oncology specialist Array BioPharma and Eli Lilly’s $8bn buyout of Loxo Oncology....
...It is also making acquisitions to bolster its position in advanced areas such as oncology, buying Array BioPharma, a Colorado-based drugmaker, in June for $10.6bn....
...The higher prices and volume growth helped power a 3 per cent rise in sales at its all important Biopharma division to $9.2bn during the first quarter....
...Siddhartha Mukherjee, the cancer geneticist and Pulitzer Prize-winning writer who is working on a novel way to expand immunotherapies for blood cancers, has raised $42m for his start-up Vor Biopharma....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...Big South Korean biopharma companies have caught the attention of global investors in recent years....
...Ms Richo, who most recently served as general counsel of Belgian biopharma company UCB, will become a member of the executive team and succeeds Laura Witte, who retired in May....
...Target: Pharmacyclics Inc | Acquirer: AbbVie Deal value $21bn | Premium 61% No auction was more hotly contested than that of Pharmacyclics, which made a single drug, Imbruvica, for blood cancer....
...Fujifilm has teamed up with a Japanese pharma company, Kyowa Hakko Kirin Biologics, and said that, by merging technologies developed through its photographic film business with Kyowa’s expertise in biopharma...
International Edition